M&A Deal Summary |
|
|---|---|
| Date | 2024-12-24 |
| Target | TRACERx |
| Sector | Life Science |
| Buyer(s) | AstraZeneca |
| Sellers(s) | Achilles Therapeutics |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 83,100 |
| Revenue | 54.1B USD (2024) |
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 20 of 22 |
| Sector (Life Science) | 18 of 20 |
| Type (Divestiture) | 5 of 6 |
| Country (United Kingdom) | 3 of 3 |
| Year (2024) | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-19 |
Fusion Pharmaceuticals
Hamilton, Ontario, Canada Fusion Pharmaceuticals is a pharmaceutical company focused on the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. Fusion Pharmaceuticals was formed in 2014 and is based in Hamilton, Ontario. |
Buy | $2.4B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-02-20 |
FibroGen China
China FibroGen China is a biopharmaceutical company. |
Buy | $160M |
| Category | Company |
|---|---|
| Founded | 2016 |
| Sector | Life Science |
| Employees | 204 |
| Revenue | 75M USD (2023) |
Achilles Therapeutics is a developer of next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. The therapies will target truncal (also known as clonal) tumor neo-antigens, unique flags to the immune system present on the surface of every cancer cell. These truncal neo-antigens are created early in cancer’s evolution and present on all cancer cells in an individual patient’s tumor but not on healthy cells, so could allow scientists to target and destroy tumors without harming healthy tissues. Achilles Therapeutics was incorporated in 2016 and is based in London, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United Kingdom) | 1 of 1 |
| Year (2024) | 1 of 1 |
